Drugs / Sym015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02648724 | Mar 2016 → Dec 2020 | non-small cell lung carcinoma | Symphogen A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sym015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02648724 ↗ |
| Action | Inhibit | “It disrupted interaction of MET with the HGF ligand and prompted activity-independent internalization and degradation of the receptor.” PMID 28802255 ↗ Aug 2017 |
| Modality | Monoclonal antibody | “Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.” NCT02648724 ↗ |
| Target | MET | “Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.” NCT02648724 ↗ |